Showing 2251-2260 of 7009 results for "".
Movements With Meaning: Reading the Pattern, Not the Label
https://reachmd.com/programs/cme/movements-with-meaning-reading-the-pattern-not-the-label/54715/Explore how clinicians differentiate tardive dyskinesia from other movement disorders using clinical features, medication timing, and response patterns.Improving Preventive Care of Patients With Hepatic Encephalopathy: Navigating the Subtleties and Beyond
https://reachmd.com/programs/cme/improving-preventive-care-of-patients-with-hepatic-encephalopathy-navigating-the-subtleties-and-beyond/36305/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
https://reachmd.com/programs/cme/translating-the-latest-kdigo-guidelines-into-practice-iv-iron-therapy-in-patients-with-nondialysis-dependent-ckd/54631/Join Drs. Núñez and Rossignol for a case-based discussion highlighting the most recent updates to the KDIGO guidelines for the management of anemia in CKD.Sniffing Out the Problem: A Dive into Management for Chronic Rhinosinusitis with Nasal Polyps
https://reachmd.com/programs/cme/sniffing-out-problem-dive-management-chronic-rhinosinusitis-nasal-polyps/11071/For the 20% of patients with chronic rhinosinusitis who develop nasal polyps, identifying the underlying cause is essential for treatment.Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/Dr. Jennifer Brown discusses CLL treatment sequencing after frontline failure, including resistance vs intolerance, MRD-guided strategies, and second-line therapy decisions.Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/Explore the latest clinical evidence on current and emerging KIT tyrosine kinase inhibitors in indolent systemic mastocytosis to optimize patient care.Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
https://reachmd.com/programs/cme/precision-strikes-in-aml-navigating-the-evolving-landscape-of-targeted-therapies/48856/Explore AML treatments targeting FLT3 and KMT2A/NPM1, focusing in on molecular diagnostics, clinical data, therapy sequencing, and adverse event management.Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
https://reachmd.com/programs/cme/emerging-focus-in-naion-sharpening-diagnostic-precision-for-tomorrows-treatments/49222/Explore diagnostic strategies and evolving therapeutic data in NAION to improve acute management, differential diagnosis, and referral readiness.Personalizing First-Line Therapy for CLL
https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/Experts explore first-line therapy selection in CLL, including biomarker testing, time-limited vs continuous regimens, safety profiles, and recent trial data.